Inclusion criteria: participants are required to meet all inclusion criteria. | |
a) Individuals ≥ 18 and ≤ 80 years old with SARS-CoV-2 infection (positive SARS-CoV-2 detection test (RT-PCR), antigenic test or equivalent < 10 days from the onset of symptoms) treated in primary care. | |
b) Persistent respiratory symptoms lasting for more than 4 weeks and less than 1 year. | |
c) Mild to moderate dyspnea: score from 1 to 3 at the beginning of the study according to the Modified Medical Research Council (mMRC) scale. | |
d) Patient must sign an informed consent form. | |
Exclusion criteria: participants meeting one or more of the following criteria will be excluded. | |
a) Severity criteria: fever> 38 °C, O2 saturation < 93%. | |
b) Patients with pneumonia in the acute/subacute phase due to SARS-Cov-2. | |
c) Patients who have required hospital admission for SARS-Cov-2. | |
d) Chronic respiratory disease: chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, pulmonary fibrosis, obstructive sleep apnea syndrome (OSAS), chronic respiratory failure from any cause, and home oxygen therapy. | |
e) Use of montelukast or zafirlukast ≤ 30 days prior inclusion. | |
f) Use of gemfibrozil. | |
g) Hypersensitivity to montelukast, lactose intolerance, or any of the excipients of study treatment or placebo. | |
h) Active malignancy and current or recent chemotherapy treatment (< 6 months). | |
i) Medical history of human immunodeficiency virus (HIV) infection or any severe immunosuppression. | |
j) Patients who have been in a clinical trial 30 days prior to the study. | |
k) Pregnancy or planning a pregnancy. | |
l) Breastfeeding mother. | |
m) The principal investigator considers that the subject will not be able to perform the test procedures. |